22-12-2022 дата публикации
Номер: US20220401452A1
Принадлежит:
Described here are methods of assessing response of a patient to an EZH2 inhibitor and methods of treating certain cancers by administering therapeutically effective amounts of an EZH2 inhibitor and a PARP-1 inhibitor. 1. A method of treating cancer in a subject in need thereof , the method comprising:administering to the subject a therapeutically effective amount of an Enhancer of Zeste Homolog 2 (EZH2) inhibitor and a poly (ADP-ribose) polymerase 1 inhibitor.2. The method of claim 1 , wherein the cancer in the subject is characterized by elevated levels of expression of one or more of Cell Division Cycle-Associated Protein 3 claim 1 , CDC28 Protein Kinase Regulatory Subunit 2 claim 1 , MutY DNA Glycosylase claim 1 , DNA Polymerase Epsilon 3 claim 1 , and Transforming Acidic Coiled-Coil Containing Protein 3 as compared to normal cells.3. The method of claim 1 , wherein the cancer is prostate cancer.4. The method of claim 1 , wherein the poly (ADP-ribose) polymerase 1 inhibitor is one or more of olaparib claim 1 , rucaparib claim 1 , niraparib (MK4827) claim 1 , talazoparib (BMN673) claim 1 , veliparib (ABT-888) claim 1 , iniparib claim 1 , pamiparib claim 1 , 3-Aminobenzamide (INO-1001) claim 1 , E7016 (GPI21016) claim 1 , CEP-8963 claim 1 , and CEP-9722.5. The method of claim 1 , wherein the poly (ADP-ribose) polymerase 1 inhibitor is olaparib.6. The method of claim 1 , wherein the EZH2 inhibitor is one or more of tazemetostat claim 1 , 3-deazaneplanocin A (DZNep) claim 1 , EPZ005687 claim 1 , EI1 claim 1 , GSK126 claim 1 , EPZ-6438 claim 1 , GSK343 claim 1 , GSK503 claim 1 , CPI-1205 claim 1 , Constellation Compound 3 claim 1 , +OR-52 claim 1 , and +UNC1999.7. The method of claim 1 , wherein the EZH2 inhibitor is tazemetostat.8. The method of claim 1 , wherein the EZH2 inhibitor is 1-[(2S)-Butan-2-yl]-N-[(4 claim 1 ,6-dimethyl-2-oxo-1H-pyridin-3-yl)methyl]-3-methyl-6-(6-piperazin-1-ylpyridin-3-yl)indole-4-carboxamide.9. A method of evaluating response of a ...
Подробнее